Protara Announces Proposed Public Offering

Rhea-AI Summary

Protara Therapeutics (Nasdaq: TARA) announced on December 4, 2025 a proposed underwritten public offering of $75 million aggregate principal amount of common stock or, for certain investors, pre-funded warrants to purchase common stock.

The company expects to grant underwriters a 30-day option to buy additional shares. Proceeds are intended to fund the clinical development of TARA-002, other clinical programs, working capital and general corporate purposes. The offering is subject to market and other conditions and will be made under a Form S-3 shelf registration declared effective on November 14, 2023. J.P. Morgan, TD Cowen and Piper Sandler are joint book-running managers.

Positive

• $75 million proposed capital raise for clinical programs
• Proceeds targeted to fund TARA-002 clinical development
• Underwritten offering with J.P. Morgan, TD Cowen, Piper Sandler

Negative

• Proposed offering may cause shareholder dilution
• No assurance the offering will be completed
• Proceeds may be used for general corporate purposes, reducing specificity

Key Figures

Proposed offering size $75 million Aggregate amount of common stock and pre-funded warrants

Underwriters’ option period 30 days Expected duration of option to purchase additional shares

Shelf form number File No. 333-275290 Form S-3 registration statement referenced for this offering

Shelf effectiveness date November 14, 2023 Date Form S-3 was declared effective by SEC

SUO Meeting number 26th Annual Referenced in background clinical conference materials

Prospectus contact phone (800) 747-3924 Piper Sandler prospectus department contact for offering documents

Market Reality Check

$6.85 Last Close

Volume Volume 1,679,363 is 2.22x the 20-day average of 757,342, indicating elevated trading interest ahead of the offering. high

Technical Trading above its 200-day MA of 3.95, with the pre-news price at 6.8 and still 35.11% below the 52-week high.

Peers on Argus 1 Up

Only 1 peer (KALA) appeared on the momentum scanner, moving up, while broader biotech peers showed mixed single-day changes, suggesting TARA’s move was stock-specific rather than a broad sector rotation.

Common Catalyst Small-cap biotech equity offerings, with both TARA and KALA announcing stock financings tagged as 'offering'.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 01	Clinical conference update	Positive	-8.7%	Announced webcast to review new Phase 2 ADVANCED-2 interim data and FDA feedback.
Nov 19	Clinical trial results	Positive	-0.6%	Reported robust interim STARBORN-1 responses for TARA-002 in pediatric lymphatic malformations.
Nov 18	Conference call announcement	Positive	+21.2%	Planned webcast to discuss interim STARBORN-1 data in pediatric lymphatic malformations.
Nov 17	Clinical data presentation	Positive	+1.1%	Planned presentation of ADVANCED-2 interim data in BCG-naïve NMIBC at SUO meeting.
Nov 10	Earnings and update	Positive	+5.6%	Q3 2025 results with cash of $133.6M, funding runway into mid-2027 and clinical milestones.

Pattern Detected

Recent clinical and earnings news skewed positive, yet two clinical updates saw negative 24h moves, while other positive events were followed by gains, indicating mixed reactions even to favorable catalysts.

Recent Company History

Over the last month, Protara issued several clinical and corporate updates, including Phase 2 data presentations for TARA-002 in NMIBC and pediatric lymphatic malformations, plus Q3 2025 results highlighting cash of $133.6 million and a runway into mid-2027. Price reactions varied: some positive clinical milestones produced gains above 20%, while other data and conference announcements led to modest declines. Today’s proposed offering to further fund TARA-002 follows this period of intensive clinical activity.

Historical Comparison

offering

+4.2 %

Average Historical Move

Historical Analysis

In the past, Protara disclosed 3 equity offerings with an average move of 4.2%. Today’s proposed $75 million raise continues the pattern of funding TARA-002 and other programs via public offerings.

Typical Pattern

Repeated public offerings have been used to finance ongoing development of TARA-002 and other clinical programs.

Regulatory & Risk Context

Short Interest

7.74%

0% 15% 30%+

moderate

Short interest at 7.74% of float with 20.66 days to cover indicates a moderately crowded short base, which can amplify volatility around capital raises and clinical catalysts.

Market Pulse Summary

The stock is dropping -11.8% following this news. A negative reaction despite ongoing clinical progress would fit the pattern where funding events and data updates sometimes met with selling, such as past moves of -6.3% around offerings and -8.67% after clinical news. The announced $75 million equity raise brings dilution concerns on top of existing short interest of 7.74% and an extended 20.66 days to cover, which can intensify downside volatility.

Key Terms

underwritten public offering financial

"it has commenced an underwritten public offering of $75 million in aggregate"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

pre-funded warrants financial

"or, in lieu of issuing common stock to certain investors, pre-funded warrants"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

underwriting discounts and commissions financial

"at the public offering price, less underwriting discounts and commissions."

Underwriting discounts and commissions are fees paid to financial institutions that help sell new securities to investors. They act like a commission for their role in connecting companies with buyers, often reducing the amount of money the issuing company raises. For investors, understanding these costs helps gauge how much of their investment is going toward the actual securities versus fees paid to middlemen.

shelf registration statement regulatory

"will be issued pursuant to a shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

Form S-3 regulatory

"shelf registration statement on Form S-3 (File No. 333-275290)"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

preliminary prospectus supplement regulatory

"only by means of a preliminary prospectus supplement and the accompanying prospectus."

A preliminary prospectus supplement is an initial document that provides important details about a new stock or bond offering before it is finalized. It helps investors understand what is being sold and why, so they can decide whether to invest. Think of it as a preview before the full sales brochure is ready.

U.S. Securities and Exchange Commission regulatory

"declared effective on November 14, 2023 by the U.S. Securities and Exchange Commission"

The U.S. Securities and Exchange Commission is a government agency responsible for overseeing the stock market and protecting investors. It sets rules to ensure that companies share truthful information and that trading is fair, helping to maintain trust in the financial system. This oversight is important because it helps prevent fraud and ensures that investors can make informed decisions.

Nasdaq financial

"Protara Therapeutics, Inc. (Nasdaq: TARA)"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

AI-generated analysis. Not financial advice.

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has commenced an underwritten public offering of $75 million in aggregate of shares of its common stock or, in lieu of issuing common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering will be offered by Protara. In addition, Protara expects to grant the underwriters a 30-day option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Protara intends to use the net proceeds received from the offering to fund the clinical development of TARA-002, as well as the development of other clinical programs. Protara may also use the net proceeds from the offering for working capital and other general corporate purposes.

J.P. Morgan, TD Cowen and Piper Sandler are acting as joint book-running managers of the proposed offering.

The shares of common stock and the pre-funded warrants will be issued pursuant to a shelf registration statement on Form S-3 (File No. 333-275290) that was declared effective on November 14, 2023 by the U.S. Securities and Exchange Commission (the “SEC”). The offering is being made only by means of a preliminary prospectus supplement and the accompanying prospectus. A preliminary prospectus supplement and the accompany prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained from the offices of J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at TDManualrequest@broadridge.com; or Piper Sandler & Co., 350 North 5^th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at prospectus@psc.com.

Before investing in the offering, interested parties should read the preliminary prospectus supplement and related prospectus for this offering, the documents incorporated by reference therein and the other documents Protara has filed with the SEC. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such state or jurisdiction.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “designed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words or expressions referencing future events, conditions or circumstances that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include but are not limited to, statements regarding the timing, size and completion of the proposed public offering as well as the expected use of proceeds related thereto are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those expressed or implied by such forward-looking statements. Factors that contribute to the uncertain nature of the forward-looking statements include: Protara’s ability to complete the offering on the proposed terms, or at all, changes in market conditions, and Protara’s expectations related to the use of proceeds from the proposed offering. Additional important factors to be considered in connection with forward-looking statements, including additional risks and uncertainties, are described more fully under the caption “Risk Factors” and elsewhere in Protara’s filings and reports with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Protara undertakes no obligation to update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as required by law.

Company Contact:

Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836

Source: Protara Therapeutics

FAQ

What is Protara (TARA) offering in the December 4, 2025 proposed public offering?

Protara is offering $75 million of common stock or pre-funded warrants, plus a 30-day option for additional shares.

How will Protara use the net proceeds from the TARA offering?

Proceeds are intended to fund the clinical development of TARA-002, other clinical programs, working capital and general corporate purposes.

Who are the underwriters for Protara's (TARA) proposed offering?

J.P. Morgan, TD Cowen and Piper Sandler are acting as joint book-running managers.

What is the impact of pre-funded warrants in the Protara (TARA) offering?

Pre-funded warrants allow certain investors to purchase shares while minimizing immediate voting dilution until exercised.

Under what registration is Protara (TARA) conducting the offering?

The offering will be issued under a Form S-3 shelf registration declared effective on November 14, 2023 (File No. 333-275290).

When could the underwriters exercise the overallotment option in the TARA offering?

Protara expects to grant a 30-day option to purchase additional shares at the public offering price.